This study is for adults (18-65 years old) with lupus nephritis (LN), a kidney problem caused by lupus, an autoimmune disease where the immune system attacks its own organs. The study checks if a new treatment, called NKX019, is safe. NKX019 uses special cells, known as CAR NK cells, to target and fight a protein called CD19. Participants will receive a series of three doses, after a preparation step with a drug called cyclophosphamide.

Key Points to Consider:

• Study Length: Involves multiple cycles and visits to the study center.
• Eligibility: Must have active LN and meet specific health criteria.
• Risks and Benefits: As a Phase 1 study, the main focus is understanding safety, so potential risks are being explored.

Participants can't join if they have severe kidney problems, heart issues, or other specific health conditions. The study is open-label, meaning both doctors and participants know about the treatment given. This study aims to help improve treatments for those dealing with lupus nephritis. If interested, ensure you meet the criteria and discuss with your doctor about joining.